ClinicalTrials.gg
Enrolling by invitationNCT06844240XEN63Updated Jun 1, 2026

Efficacy and Safety of XEN63 Gel Implant

An observational study in Glaucoma, sponsored by Mario Stirpe. Enrolling by invitation at 19 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Mario Stirpe · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
96
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 53 studies in Glaucoma with a site in Italy — 7 open to participants now, 8 under way, 1 of them phase 3. Glaucoma · Italy.

Planned enrollment
9th of 13
96 · median 200
Started
2024
with 2 others
Observational
13 of 53
6 open now
Registered
47th of 53
by date

Among the 53 studies in Glaucoma with a site in Italy, this one is the 9th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, and was the 47th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

7 of the 53 studies in Glaucoma with a site in Italy are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Glaucoma with a site in Italy, or all of them as a file.
02

Study summary

The study is prospective, observational, multicenter and has the aim of evaluating the efficacy and safety of the XEN63 implant in patients with primary or secondary glaucoma who require surgery in association or not with cataract surgery, for IOP not controlled by medical therapy, disease progression or intolerance to topical therapy, comparing IOP values before and 24 months after implantation.

Read the detailed description

The study is prospective, observational, multicenter and has the aim of evaluating the efficacy and safety of the XEN63 implant in patients with primary or secondary glaucoma who require surgery in association or not with cataract surgery, for IOP not controlled by medical therapy, disease progression or intolerance to topical therapy, comparing IOP values before and 24 months after implantation. Every patients will be followed for 24 months.

Secondary aims of the study are:

  • Evaluating the hypotensive efficacy of the XEN63 12 months after implantation.
  • Assessing the safety of the XEN63 device after 12 and 24 months after implantation.
  • Comparing the hypotensive efficacy of the XEN63 in glaucomatous patients undergoing the solo procedure and in those undergoing the combo procedure
  • Evaluating the quality of life of patients undergoing XEN63 implantation 12 and 24 months after implantation.
  • Evaluating the association between factors related to the patient, the surgical technique or post-operative management and the hypotensive efficacy of the device during follow-up.
03

Conditions studied

  • Glaucoma

Browse trials for

Keywords

  • glaucoma
  • surgery
  • XEN63
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Glaucoma patients attending the hospital

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Diagnosis of primary or secondary open-angle glaucoma according to the diagnostic criteria of 4th edition of the European Glaucoma Society Guidelines.
  3. Need for XEN63 implantation for IOP not controlled by medical therapy, progression of disease or intolerance to topical therapy, in association or not with cataract surgery.
  4. freely given and obtained before the start of the study.
  5. The participant has the ability to understand and the willingness to follow the study instructions and is likely to complete all required visits and procedures.

Exclusion criteria

Exclusion Criteria:

  1. Closed-angle glaucoma
  2. Previous trabeculectomy or valve or tube placement.
  3. Presence of conjunctival scarring, previous conjunctival surgery or other conjunctival pathologies (e.g. pterygium) in the target quadrant.
  4. Signs of active inflammation (e.g. blepharitis, conjunctivitis, keratitis, uveitis)
  5. Active iris neovascularization or presence of iris new vessels within 6 months of the date of surgery
  6. Anterior chamber lenses
  7. Presence of intraocular silicone oil
  8. Vitreous in anterior chamber
  9. Altered episcleral venous drainage (e.g. Sturge Webwer syndrome, nanophthalmos)
  10. Known or suspected allergy or sensitization to medications required for the surgical procedure or some component of the device (e.g. glutaraldehyde or porcine derivatives)
  11. History of predisposition to the formation of keloids.
  12. Pregnancy or breastfeeding.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
96 participants (estimated)
Target follow-up
24 Months
Patient registry
Yes

Groups and cohorts

  • Glaucoma

    Diagnosis of primary or secondary open-angle glaucoma according to the diagnostic criteria of 4th edition of the European Glaucoma Society Guidelines.

06

What researchers measure

Primary outcomes

  1. IOP

    IOP values before and after 24 months of XEN63 implant.

    Time frame: up to 2 years

  2. Number of hypotensive eye drops

    Number of hypotensive eye drops

    Time frame: up to 2 years

Secondary outcomes

  1. IOP

    IOP values before and after 12 months of XEN63 implant.

    Time frame: From enrollment to 12 months after surgery

  2. Number of hypotensive eye drops

    Number of hypotensive eye drops before and after 12 months of XEN63 implant

    Time frame: From enrollment to 12 months after surgery

  3. Complications

    \- Type and number of intraoperative and postoperative complications.

    Time frame: up to 2 years

  4. Quality of life after XEN63 implant

    Quality of life questionnaire (National Eye Institute Visual Function Questionnaire-25) scores over time. The minimum value is 0, the maximum value is 100. Higher score means a better outcome.

    Time frame: up to 2 years

  5. Surgical tecnique

    Data on surgical technique: site of XEN63 implant

    Time frame: during the intervention/procedure/surgery

  6. Post operative management

    Post operative treatment: type of steroids used

    Time frame: up to 2 years

  7. Post operative needling

    Number of needling

    Time frame: up to 2 years

  8. Surgical revision

    Number of surgical revision

    Time frame: up to 2 years

  9. Glaucoma Symptom Scale

    A brief symptom survey specific for persons with glaucoma. This score is transformed to a 0 to 100 scale, with 0 representing presence of a very bothersome problem and 100 representing absence of a problem.

    Time frame: up to 2 years

  10. Surgical technique

    Data on surgical technique: type of viscoelastic used

    Time frame: during the intervention/procedure/surgery

  11. Post operative management

    Type and number of hypotensive drops used to control IOP after surgery if needed.

    Time frame: up to 2 years

07

Study locations

19 sites
  • Ente ecclesiastico Ospedale Generale Regionale F. Miulli-Acquaviva delle Fonti Bari
    Acquaviva delle Fonti, Italy 70021, Italy
  • Ospedale della Murgia "Fabio Perinei"
    Altamura, Italy 70022, Italy
  • Ospedale Santa Croce e Carle di Cuneo
    Cuneo, Italy 12100, Italy
  • SOD Oculistica - AOU Careggi, Firenze
    Florence, Italy 50134, Italy
  • AUSL di Piacenza UOC Oculistica, Ospedale "Guglielmo da Saliceto
    Piacenza, Italy 29121, Italy
  • Azienda Ospedaliera Universitaria di Sassari, Dipartimento di Medicina, Chirurgia e Farmacologia Università di Sassari
    Sassari, Italy 07100, Italy
  • UOC Oculistica Aulss 4, Ospedale di San Donà Di Piave.
    Venezia, Italy 30027, Italy
  • Ospedale S. Andrea, S.O.C. Oculistica
    Vercelli, Italy, Italy
  • ASST Papa Giovanni XXIII
    Bergamo, Italy
  • Clinica Oculistica, Ospedale San Giovanni di Dio, Azienda Ospedaliero-Universitaria di Cagliari
    Cagliari, Italy
  • Clinica Oculistica c/o Azienda Ospedale - Università di Padova
    Padova, Italy
  • Dipartimento di Scienze Clinico-Chirurgiche, Diagnostiche e Pediatriche, Fondazione IRCCS policlinico San Matteo di Pavia
    Pavia, Italy
  • Dipartimento di Medicina e Scienze dell'Invecchiamento, Università G.D'Annunzio di Chieti-Pescara
    Pescara, Italy
  • Clinica Oculistica Universitaria Ospedale Santa Chiara, AOUP-Ospedale Cisanello
    Pisa, Italy
  • IRCCS-Fondazione GB Bietti
    Rome, 00184, Italy
  • CET Interaziendale AOU Città della Salute e della Scienza di Torino
    Torino, Italy
  • Ospedale Ca'Foncello AULSS 2 Marca Trevigiana
    Treviso, Italy
  • Azienda ospedaliera 'C.Panico' Tricase Lecce
    Tricase, Italy
  • Day service di Oculistica del PPA "F.Fallacara"
    Triggiano, Italy
08

References and documents

Publications

  • Fea AM, Menchini M, Rossi A, Posarelli C, Malinverni L, Figus M. Early Experience with the New XEN63 Implant in Primary Open-Angle Glaucoma Patients: Clinical Outcomes. J Clin Med. 2021 Apr 12;10(8):1628. doi: 10.3390/jcm10081628. PubMed 33921311 ↗
  • Lavia C, Dallorto L, Maule M, Ceccarelli M, Fea AM. Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: A systematic review and meta-analysis. PLoS One. 2017 Aug 29;12(8):e0183142. doi: 10.1371/journal.pone.0183142. eCollection 2017. PubMed 28850575 ↗
  • Fannin LA, Schiffman JC, Budenz DL. Risk factors for hypotony maculopathy. Ophthalmology. 2003 Jun;110(6):1185-91. doi: 10.1016/S0161-6420(03)00227-6. PubMed 12799246 ↗
  • Bashford KP, Shafranov G, Shields MB. Bleb revision for hypotony maculopathy after trabeculectomy. J Glaucoma. 2004 Jun;13(3):256-60. doi: 10.1097/00061198-200406000-00015. PubMed 15118473 ↗
  • Bitrian E, Song BJ, Caprioli J. Bleb revision for resolution of hypotony maculopathy following primary trabeculectomy. Am J Ophthalmol. 2014 Sep;158(3):597-604.e1. doi: 10.1016/j.ajo.2014.05.021. Epub 2014 May 27. PubMed 24874999 ↗
  • Oyakhire JO, Moroi SE. Clinical and anatomical reversal of long-term hypotony maculopathy. Am J Ophthalmol. 2004 May;137(5):953-5. doi: 10.1016/j.ajo.2003.11.019. PubMed 15126172 ↗
  • Costa VP, Arcieri ES. Hypotony maculopathy. Acta Ophthalmol Scand. 2007 Sep;85(6):586-97. doi: 10.1111/j.1600-0420.2007.00910.x. Epub 2007 Jun 2. PubMed 17542978 ↗
  • Jampel HD, Musch DC, Gillespie BW, Lichter PR, Wright MM, Guire KE; Collaborative Initial Glaucoma Treatment Study Group. Perioperative complications of trabeculectomy in the collaborative initial glaucoma treatment study (CIGTS). Am J Ophthalmol. 2005 Jul;140(1):16-22. doi: 10.1016/j.ajo.2005.02.013. PubMed 15939389 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Dec 2030, 73 months after the start.

Of 111 non-industry observational studies under Glaucoma, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 208. This study's planned 73 months is above that.

Counting every sponsor, half of 135 studies reached it within 31 months; a quarter within 11 and three quarters within 208.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2025
First posted
Feb 25, 2025
StartActual
Nov 28, 2024
Primary completionEst.
Dec 31, 2030
CompletionEst.
Dec 31, 2030
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06844240
Lead sponsor
Mario Stirpe
Responsible party
Mario Stirpe (Prof, Fondazione G.B. Bietti, IRCCS) — Sponsor-investigator
First posted
Feb 25, 2025
Start date
Nov 28, 2024
Primary completion
Dec 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Jun 1, 2026

Study contacts

Francesco Oddone, MD, PhD
principal investigator · IRCCS-Fondazione GB Bietti

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion